Diversified Trust Co raised its holdings in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) by 6.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,246 shares of the company’s stock after buying an additional 2,544 shares during the period. Diversified Trust Co’s holdings in AbbVie were worth $7,211,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. Oliver Lagore Vanvalin Investment Group raised its stake in shares of AbbVie by 85.3% during the third quarter. Oliver Lagore Vanvalin Investment Group now owns 202 shares of the company’s stock valued at $27,000 after purchasing an additional 93 shares during the period. Align Wealth Management LLC purchased a new stake in shares of AbbVie during the fourth quarter valued at approximately $27,000. Red Tortoise LLC purchased a new stake in shares of AbbVie during the fourth quarter valued at approximately $27,000. Boulder Wealth Advisors LLC purchased a new stake in shares of AbbVie during the fourth quarter valued at approximately $31,000. Finally, My Personal CFO LLC purchased a new stake in shares of AbbVie during the fourth quarter valued at approximately $32,000. 68.27% of the stock is owned by institutional investors and hedge funds.
AbbVie Stock Performance
AbbVie stock opened at $138.64 on Tuesday. The company has a market cap of $244.60 billion, a PE ratio of 32.78, a P/E/G ratio of 2.53 and a beta of 0.58. The company has a fifty day moving average price of $146.96 and a two-hundred day moving average price of $152.72. The company has a debt-to-equity ratio of 4.46, a current ratio of 0.96 and a quick ratio of 0.82. AbbVie Inc. has a 12 month low of $131.10 and a 12 month high of $168.11.
Insider Activity
In related news, EVP Perry C. Siatis sold 3,520 shares of the company’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $160.00, for a total value of $563,200.00. Following the completion of the sale, the executive vice president now owns 10,377 shares of the company’s stock, valued at $1,660,320. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Perry C. Siatis sold 3,520 shares of the company’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $160.00, for a total value of $563,200.00. Following the completion of the sale, the executive vice president now owns 10,377 shares of the company’s stock, valued at $1,660,320. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Elaine K. Sorg sold 7,499 shares of the company’s stock in a transaction dated Monday, April 17th. The stock was sold at an average price of $161.67, for a total transaction of $1,212,363.33. Following the completion of the sale, the senior vice president now directly owns 35,330 shares of the company’s stock, valued at approximately $5,711,801.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,151 shares of company stock valued at $5,187,783. 0.26% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on ABBV shares. Wells Fargo & Company dropped their price objective on shares of AbbVie from $200.00 to $195.00 in a research note on Friday, April 28th. Barclays lifted their price objective on shares of AbbVie from $155.00 to $160.00 in a research note on Wednesday, April 12th. StockNews.com started coverage on shares of AbbVie in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. Argus lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Wednesday, April 5th. Finally, Morgan Stanley lifted their price target on shares of AbbVie from $178.00 to $181.00 and gave the stock an “overweight” rating in a research note on Monday, April 10th. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $163.40.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.
See Also
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- Trading Stocks: RSI and Why it’s Useful
- Why Mosaic’s Price Targets May Be Understated
- Amazon And The AI War: iRobot Acquisition In Focus
- What Does Logitech CEO’s Abrupt Departure Mean?
- Ulta Beauty Stock Value is More Than Skin Deep
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Get Rating).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
